You are here

Upper

Investors

Here, you'll find stock and share information, plus a quarter by quarter record of financial statements and management analyses.

Please click here to view an interview with Andrew Morris our CEO and President

Please download our most recent investor presentation

To listen to our Q2 2016 earning call click here

To sign up for media updates, please click here and ask to be added to our Investor Relations distribution list.

Lower
Multiplexing and the market

Lets start with an an overview of our value proposition, which all starts with multiplexing.

mul·ti·plex
verb /‘məl-tē -, pleks/
to detect multiple analytes from a single biological specimen, often in an automated fashion.

SQI Diagnostics was founded in 1999 to reduce the number of blood tests necessary to diagnose disease. We’ve invested more than $45 million dollars to develop automated systems that enable customers to produce many test results from a single sample—saving time and cost. Our multiplexed diagnostic tests target two large markets:

  1. Diagnostic testing laboratories, where our rheumatoid and celiac diagnostics tests have been cleared by the U.S. FDA
  2. Drug development markets, where global pharmaceutical companies currently spend many man days testing each "patient" in their drug development programs

Proven and published

Pharmaceutical development customers have publically stated the superior technical performance of our products.

Our tests significantly decrease the total cost of delivery for drug development programs and diagnostics testing laboratories by markedly reducing the tests and labor involved.

In addition to the benefits of our patented multiplexing, we also sell high throughput automated systems on which our customers run the tests.

Business developments

Our value proposition is consistent across our target markets. We provide state-of-the-art platforms which utilize custom-built test kits to reduce the amount of human labour required while delivering superior assay performance. We do this through “multiplexing” and automation.

Since developing custom tests for pharmaceutical and biotechnology drug developers, clinical research organizations, and diagnostic customers, SQI has created a broad range of applications of its multiplexing technology. SQI has quickly moved from being a new entrant in the market and has advanced to the point of developing customers within big pharma for testing SQI immunogenicity diagnostic testing products and development services.

We expect to add further customers in the quarters to come and to place and sell more platforms in order to build a solid foundation for future growth from kit sales. This also includes Contract Research Organizations (“CRO”) service-based revenue earned from running tests for customers at our facilities based on the multiplexed tests developed. The CRO revenue represents the combination of kit sales and the service revenues from running tests and generating data for pre-clinical studies. In addition to the successful commercialization in the Life Science Research market, we have had positive outcomes in the multiplexing of existing traditional singleplex tests in the animal health sector.

As we continue to commercialize our multiplexing platforms and kits, we are engaging more pharmaceutical clients and ramping up revenues from platform placements, development revenue, and kit sales.

The next step with our customers is to establish SQI platforms at their laboratories for final evaluation, which once achieved will lead to our ultimate objective of selling them significant volumes of customized kits for their on-going testing needs. We would estimate that each platform would generate between $1 and $2 million of revenue per year from kit sales and that the larger customers could acquire several platforms as we broaden the application of our technology.

The future

There are 112 drugs being developed by customers who have signed a Master Service Agreement with SQI Diagnostics. We estimate that the market for multiplexed testing by North American and European pharmaceutical companies is approximately $2.0 billion. In the U.S. alone, there are almost 1,000 biologic drugs under development.

We continue to develop in vitro diagnostic tests targeting testing labs. We estimate that our products could reduce their labor costs by as much as 40%. There are 1,000 such labs in the U.S.

Stock information

SQD (common stock)
Shares issued and outstanding: 56.3 M
Year end: September 30

Exchange: TSX-Venture
Symbol: SQD
Stock quote: SQD-V

Exchange: OTCQX
Symbol: SQIDF
Stock quote: SQIDF

Review our stock option plan.

For more information, please contact our Vice President of Finance, Patricia Lie, Tel +1 416-674-9500 x277.

Financial statements and analysis

2016
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2015
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2014
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2013
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2012
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2011
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2010
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2009
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
2008
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis
 
Consolidated Financial Statement
 
Management Discussion & Analysis